Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
Earnings Data
Report Date
May 15, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -35.56%
|Next Earnings Date:May 15, 2025
Earnings Call Sentiment|Positive
The earnings call highlights substantial progress in the TECELRA launch, strong manufacturing and reimbursement success, and promising developments for future products like Lete-cel. However, the company faces challenges in securing additional capital to reach profitability by 2027 and delayed financial reporting. Overall, the positive aspects, particularly in product launch and efficiency, outweigh the financial and capital concerns.Company Guidance
During Adaptimmune's Q4 and full-year 2024 business update call, the company provided several key metrics and guidance that highlighted the promising trajectory of their TECELRA product launch. They reported having 20 authorized treatment centers (ATCs) established, representing two-thirds of their planned network of 30 sites, well ahead of their original schedule to complete by late 2026. In Q4 2024, they apheresed three patients, generating $1.2 million in revenue from two invoiced patients. For Q1 2025, they have already apheresed 10 patients and anticipate apheresing a total of 13 by the end of March, expecting invoicing for 6 to 8 patients. The company has successfully secured reimbursement policies covering over 70% of commercial and Medicare lives. Manufacturing has met all targets, with 100% of products manufactured to specification and a turnaround time of less than the targeted 30 days. Adaptimmune anticipates sales of TECELRA to continue accelerating and sees the analyst consensus forecast of approximately $25 million in sales for 2025 as achievable. Furthermore, they foresee US peak sales for their sarcoma franchise, including TECELRA and the upcoming Lete-cel, to reach approximately $400 million. Adaptimmune also announced cost-saving measures by pausing investments in preclinical programs, aiming to reduce cash flow demands by $75 million to $100 million through 2028, in addition to $300 million from previous restructuring efforts. These initiatives are aligned with their goal of achieving cash flow breakeven by 2027.Successful TECELRA Launch
The TECELRA launch has shown fantastic momentum with 20 authorized treatment centers representing two-thirds of the planned network, ahead of schedule. In Q1 2025, they've apheresed 10 patients with expectations to invoice 3 to 4 times as many patients as in the prior quarter.
Promising Reimbursement Success
Over 70% of commercial and Medicare lives are in plans with policies to cover TECELRA, with zero reimbursement denials to date, showcasing strong support from payers.
Manufacturing Efficiency
TECELRA manufacturing has been highly efficient with a 100% success rate in product release and no manufacturing failures. The turnaround time is less than the target of 30 days.
Lete-cel Progress
Lete-cel, the next product in the sarcoma franchise, is on track for BLA submission later this year. The IGNYTE-ESO trial showed a 42% overall response rate, with six complete responses among 64 patients.
Cost-Saving Measures
The company has announced a pause on spending for preclinical programs targeting PRAME and CD70, reducing forward cash flow demands by $75 million to $100 million, in addition to $300 million saved from previous restructuring.
---
ADAP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADAP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $0.45 | $0.28 | -37.78% |
| Nov 13, 2024 | $0.77 | $0.59 | -23.38% |
| Aug 12, 2024 | $0.99 | $1.09 | +10.10% |
| May 15, 2024 | $1.15 | $1.24 | +7.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Adaptimmune Therapeutics (ADAP) report earnings?
Adaptimmune Therapeutics (ADAP) is schdueled to report earning on May 15, 2025, TBA Not Confirmed.
What is Adaptimmune Therapeutics (ADAP) earnings time?
Adaptimmune Therapeutics (ADAP) earnings time is at May 15, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADAP EPS forecast?
ADAP EPS forecast for the fiscal quarter 2025 (Q1) is -0.13.
---
